alenza 225/55r19的問題，透過圖書和論文來找解法和答案更準確安心。 我們找到下列包括價格和評價等資訊懶人包

利用組織微陣列評估GIT-1與犬隻乳房腫瘤之相關性:2005-2009

為了解決alenza 225/55r19的問題，作者康文 這樣論述：

Mammary gland tumors are among the most common tumors of the female dog. Recent studies have shown multiple risk factors and over-expressions of proteins that are highly associated with patient prognosis and overall survival. GIT-1 is a protein that appears to be associated with the regulation of c

ytoskeleton dynamics during cell spreading and migration. Recent evidence suggests that GIT-1 could be involved in human Huntington’s disease due to altered membrane trafficking. The role of GIT-1 over-expression in canine mammary gland tumor is currently unknown. However, through the microarray tec

hniques adopted in this study, immunohistochemistry (IHC) significance of 90% was noted. Our goal is to identify the significance of GIT-1 IHC staining in canine mammary gland tumor and further connect these results with their clinical prognosis. 61 cases were collected through the years of 2005 to

2009. 58 dogs (95%) came up with a positive GIT-1 staining result. The dogs were grouped according to their IHC scores. The group with the higher IHC scores (≥3) reached an median survival of 361 days, whereas the lower IHC scoring group (≤2) had a median survival of 574 days, no significance was no

ted (p=0.94). The patient’s GIT1 significance were also compared with its WHO modified TNM staging scores, however still no significance was achieved (p=0.117). Nevertheless, we did manage to prove that the TNM staging system provided a rough understanding of the patient’s survival (p=0.015). We con

clude that there was no significance noted between IHC scorings and patient prognosis.

內分泌受器表現於母犬惡性乳腺腫瘤之預後潛力

為了解決alenza 225/55r19的問題，作者蔡旻烜 這樣論述：

內分泌透過分佈於母犬乳腺的受器在乳腺腫瘤的形成過程扮演很重要的角色 (Misdorp et al., 1988; Gustafsson et al., 1999)。已知動情素受器 (estrogen receptor-α, -β, ER-α,-β) 及黃體助孕素受器 (progesterone receptor, PR) 的表現與其他已被確認的預後因子，如腫瘤大小，組織學分級等有相關性。因此，本實驗以免疫組織化學研究113隻罹患乳腺腫瘤的母犬，包括89個惡性腫瘤及24個良性腫瘤病例，其腫瘤中ER-α、ER-β及PR的表現情形。結果顯示，ER-α,-β及PR在腫瘤中的陽性率分別為60.2 %、

95.6 %和77.9%。這些陽性病例中，ER-α (p